Large Simple Trials Need FDA Boost, IoM Report Says
Executive Summary
“Clear specific guidance” from the agency would help close the perception gap between what types of data industry thinks FDA wants and what the agency actually expects, according to a summary of a 2012 Institute of Medicine workshop.
You may also be interested in...
FDA’s Temple Pushes Feasibility, Cost-Savings Of Large, Simple Trials
New tools and funding priorities support large, simple trials, now industry needs to get on board to create a more efficient, cost-effective health system, JAMA editorial says.
FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle
Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.
Merck’s Vorapaxar CV Outcome Follow-Up Success Not Ready To Become Standard
Cardiovascular and Renal Drugs Advisory Committee says FDA should encourage lost-to-follow-up rates closer to what was seen in Merck’s TRA2P study of vorapaxar, but shouldn’t expect it.